Erleada (apalutamide)
Indications for Prior Authorization
Erleada (apalutamide)
-
For diagnosis of Non-metastatic castration-resistant prostate cancer
Indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC).
Erleada (apalutamide)
-
For diagnosis of Metastatic castration-sensitive prostate cancer
Indicated for the treatment of patients with metastatic, castration-sensitive prostate cancer (M-CSPC).
Criteria
Erleada
Prior Authorization (Initial Authorization)
Length of Approval: 12 Month(s)
- Diagnosis of prostate cancer
Erleada
Prior Authorization (Reauthorization)
Length of Approval: 12 Month(s)
- Patient does not show evidence of disease progression while on therapy
P & T Revisions
2024-05-20, 2023-07-05, 2023-05-04, 2023-04-07, 2022-04-07, 2021-11-01, 2021-04-08, 2020-04-28, 2020-01-27, 2019-10-28
References
- Erleada prescribing information. Janssen Ortho LLC. Gurabo, PR. December 2023.
Revision History
- 2024-05-20: 2024 UM Annual Review. Combined CRPC and CSPC into one criteria bucket and updated criteria to just require diagnosis of prostate cancer. Background updates.
- 2023-07-05: Removed specialist requirement
- 2023-05-04: Updated criteria and background.
- 2023-04-07: Annual review: No criteria changes. Added new Erleada 240 mg tablet formulation to existing criteria sets. Updated references.
- 2022-04-07: Annual review: No criteria changes. Updated references.
- 2021-11-01: Remove trial and failure requirement through Xtandi or Nubeqa due to formulary strategy.
- 2021-04-08: annual review: updated references
- 2020-04-28: Annual Review: no criteria changes
- 2020-01-27: revised criteria
- 2019-10-28: Updated guideline with new indication
HEALTHY LIVING